Skip to content

Pfizer

NYSE: PFE · USD

Pfizer financials

6 charts

Revenue

USD millions

$15,034M
Pfizer Revenue. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodRevenue
FY 2009 Q2$10,984M; Change unavailable vs FY 2009 Q1
FY 2009 Q3$11,621M; +5.8% vs FY 2009 Q2
FY 2009 Q4$16,537M; +42.3% vs FY 2009 Q3
FY 2010 Q1$16,750M; +1.3% vs FY 2009 Q4
FY 2010 Q2$17,327M; +3.4% vs FY 2010 Q1
FY 2010 Q3$16,171M; −6.7% vs FY 2010 Q2
FY 2010 Q4$17,561M; +8.6% vs FY 2010 Q3
FY 2011 Q1$16,502M; −6.0% vs FY 2010 Q4
FY 2011 Q2$16,984M; +2.9% vs FY 2011 Q1
FY 2011 Q3$17,193M; +1.2% vs FY 2011 Q2
FY 2011 Q4$16,746M; −2.6% vs FY 2011 Q3
FY 2012 Q1$15,405M; −8.0% vs FY 2011 Q4
FY 2012 Q2$15,057M; −2.3% vs FY 2012 Q1
FY 2012 Q3$13,976M; −7.2% vs FY 2012 Q2
FY 2012 Q4$15,068M; +7.8% vs FY 2012 Q3
FY 2013 Q1$13,500M; −10.4% vs FY 2012 Q4
FY 2013 Q2$12,973M; −3.9% vs FY 2013 Q1
FY 2013 Q3$12,643M; −2.5% vs FY 2013 Q2
FY 2013 Q4$13,558M; +7.2% vs FY 2013 Q3
FY 2014 Q1$11,353M; −16.3% vs FY 2013 Q4
FY 2014 Q2$12,773M; +12.5% vs FY 2014 Q1
FY 2018 Q2$13,466M; Change unavailable vs FY 2018 Q1
FY 2018 Q3$13,298M; −1.2% vs FY 2018 Q2
FY 2018 Q4$13,977M; +5.1% vs FY 2018 Q3
FY 2019 Q1$13,118M; −6.1% vs FY 2018 Q4
FY 2019 Q2$13,264M; +1.1% vs FY 2019 Q1
FY 2019 Q3$12,680M; −4.4% vs FY 2019 Q2
FY 2019 Q4$12,688M; +0.1% vs FY 2019 Q3
FY 2020 Q1$12,028M; −5.2% vs FY 2019 Q4
FY 2020 Q2$11,801M; −1.9% vs FY 2020 Q1
FY 2020 Q3$12,131M; +2.8% vs FY 2020 Q2
FY 2020 Q4$5,947M; −51.0% vs FY 2020 Q3
FY 2021 Q1$14,582M; +145.2% vs FY 2020 Q4
FY 2021 Q2$18,977M; +30.1% vs FY 2021 Q1
FY 2021 Q3$24,094M; +27.0% vs FY 2021 Q2
FY 2021 Q4$23,635M; −1.9% vs FY 2021 Q3
FY 2022 Q1$25,661M; +8.6% vs FY 2021 Q4
FY 2022 Q2$27,742M; +8.1% vs FY 2022 Q1
FY 2022 Q3$22,638M; −18.4% vs FY 2022 Q2
FY 2022 Q4Unavailable; Change unavailable vs FY 2022 Q3
FY 2023 Q1$18,282M; Change unavailable vs FY 2022 Q4
FY 2023 Q2$12,734M; −30.3% vs FY 2023 Q1
FY 2023 Q3$13,232M; +3.9% vs FY 2023 Q2
FY 2023 Q4Unavailable; Change unavailable vs FY 2023 Q3
FY 2024 Q1$14,879M; Change unavailable vs FY 2023 Q4
FY 2024 Q2$13,283M; −10.7% vs FY 2024 Q1
FY 2024 Q3$17,702M; +33.3% vs FY 2024 Q2
FY 2024 Q4$17,763M; +0.3% vs FY 2024 Q3
FY 2025 Q1$13,715M; −22.8% vs FY 2024 Q4
FY 2025 Q2$14,653M; +6.8% vs FY 2025 Q1
FY 2025 Q3$16,654M; +13.7% vs FY 2025 Q2
FY 2025 Q4$17,557M; +5.4% vs FY 2025 Q3
FY 2026 Q1$14,451M; −17.7% vs FY 2025 Q4
FY 2026 Q2$15,034M; +4.0% vs FY 2026 Q1
Jun 28, 2009 through Sep 25, 2026

Free cash flow

USD millions

$302M
Pfizer Free cash flow. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodFree cash flow
FY 2009 Q2$4,245M; Change unavailable vs FY 2009 Q1
FY 2009 Q3$3,840M; −9.5% vs FY 2009 Q2
FY 2009 Q4$4,403M; +14.7% vs FY 2009 Q3
FY 2010 Q1$-6,665M; −251.4% vs FY 2009 Q4
FY 2010 Q2$4,500M; +167.5% vs FY 2010 Q1
FY 2010 Q3$6,395M; +42.1% vs FY 2010 Q2
FY 2010 Q4$5,711M; −10.7% vs FY 2010 Q3
FY 2011 Q1$4,392M; −23.1% vs FY 2010 Q4
FY 2011 Q2$5,540M; +26.1% vs FY 2011 Q1
FY 2011 Q3$3,985M; −28.1% vs FY 2011 Q2
FY 2011 Q4$4,663M; +17.0% vs FY 2011 Q3
FY 2012 Q1$2,520M; −46.0% vs FY 2011 Q4
FY 2012 Q2$3,727M; +47.9% vs FY 2012 Q1
FY 2012 Q3$4,718M; +26.6% vs FY 2012 Q2
FY 2012 Q4$4,762M; +0.9% vs FY 2012 Q3
FY 2013 Q1$2,039M; −57.2% vs FY 2012 Q4
FY 2013 Q2$3,521M; +72.7% vs FY 2013 Q1
FY 2013 Q3$5,630M; +59.9% vs FY 2013 Q2
FY 2013 Q4$5,369M; −4.6% vs FY 2013 Q3
FY 2014 Q1$2,643M; −50.8% vs FY 2013 Q4
FY 2014 Q2$3,809M; +44.1% vs FY 2014 Q1
FY 2018 Q2$3,423M; Change unavailable vs FY 2018 Q1
FY 2018 Q3$4,712M; +37.7% vs FY 2018 Q2
FY 2018 Q4$4,053M; −14.0% vs FY 2018 Q3
FY 2019 Q1$1,238M; −69.5% vs FY 2018 Q4
FY 2019 Q2$2,132M; +72.2% vs FY 2019 Q1
FY 2019 Q3$3,945M; +85.0% vs FY 2019 Q2
FY 2019 Q4$3,097M; −21.5% vs FY 2019 Q3
FY 2020 Q1$2,670M; −13.8% vs FY 2019 Q4
FY 2020 Q2$3,076M; +15.2% vs FY 2020 Q1
FY 2020 Q3$1,565M; −49.1% vs FY 2020 Q2
FY 2020 Q4$4,840M; +209.3% vs FY 2020 Q3
FY 2021 Q1$3,984M; −17.7% vs FY 2020 Q4
FY 2021 Q2$10,759M; +170.1% vs FY 2021 Q1
FY 2021 Q3$10,205M; −5.1% vs FY 2021 Q2
FY 2021 Q4$4,921M; −51.8% vs FY 2021 Q3
FY 2022 Q1$5,898M; +19.9% vs FY 2021 Q4
FY 2022 Q2$7,419M; +25.8% vs FY 2022 Q1
FY 2022 Q3$5,133M; −30.8% vs FY 2022 Q2
FY 2022 Q4$7,581M; +47.7% vs FY 2022 Q3
FY 2023 Q1$73M; −99.0% vs FY 2022 Q4
FY 2023 Q2$-2,122M; −3006.8% vs FY 2023 Q1
FY 2023 Q3$2,646M; +224.7% vs FY 2023 Q2
FY 2023 Q4$4,196M; +58.6% vs FY 2023 Q3
FY 2024 Q1$386M; −90.8% vs FY 2023 Q4
FY 2024 Q2$-2,418M; −726.4% vs FY 2024 Q1
FY 2024 Q3$6,063M; +350.7% vs FY 2024 Q2
FY 2024 Q4$5,804M; −4.3% vs FY 2024 Q3
FY 2025 Q1$1,771M; −69.5% vs FY 2024 Q4
FY 2025 Q2$-1,200M; −167.8% vs FY 2025 Q1
FY 2025 Q3$4,001M; +433.4% vs FY 2025 Q2
FY 2025 Q4$4,503M; +12.5% vs FY 2025 Q3
FY 2026 Q1$2,179M; −51.6% vs FY 2025 Q4
FY 2026 Q2$302M; −86.1% vs FY 2026 Q1

Net margin

%

-1.65%
Pfizer Net margin. Reported fiscal history.
Fiscal period%
FY 2009 Q220.58%
FY 2009 Q324.77%
FY 2009 Q44.64%
FY 2010 Q112.1%
FY 2010 Q214.28%
FY 2010 Q35.36%
FY 2010 Q416.46%
FY 2011 Q113.47%
FY 2011 Q215.37%
FY 2011 Q321.74%
FY 2011 Q48.59%
FY 2012 Q111.65%
FY 2012 Q221.6%
FY 2012 Q322.95%
FY 2012 Q441.91%
FY 2013 Q120.37%
FY 2013 Q2108.65%
FY 2013 Q320.49%
FY 2013 Q418.94%
FY 2014 Q120.51%
FY 2014 Q222.8%
FY 2018 Q228.75%
FY 2018 Q330.94%
FY 2018 Q4-2.81%
FY 2019 Q129.61%
FY 2019 Q238.04%
FY 2019 Q360.57%
FY 2019 Q4-2.65%
FY 2020 Q128.28%
FY 2020 Q229.03%
FY 2020 Q318.09%
FY 2020 Q49.99%
FY 2021 Q133.45%
FY 2021 Q229.31%
FY 2021 Q333.81%
FY 2021 Q414.36%
FY 2022 Q130.65%
FY 2022 Q235.71%
FY 2022 Q338.02%
FY 2022 Q4—
FY 2023 Q130.32%
FY 2023 Q218.27%
FY 2023 Q3-18%
FY 2023 Q4—
FY 2024 Q120.94%
FY 2024 Q20.31%
FY 2024 Q325.22%
FY 2024 Q42.31%
FY 2025 Q121.63%
FY 2025 Q219.86%
FY 2025 Q321.26%
FY 2025 Q4-9.39%
FY 2026 Q118.59%
FY 2026 Q2-1.65%

P/E

× · TTM · Daily

37.72×
Pfizer P/E. Monthly closing observations; inspect daily values with the chart arrow keys.
Close date× · TTM · DailyFinancials through
2010-03-3115.61×2009-12-31
2010-04-3015.22×2009-12-31
2010-05-2815.55×2010-04-04
2010-06-3014.56×2010-04-04
2010-07-3015.32×2010-04-04
2010-08-3115.77×2010-07-04
2010-09-3017.02×2010-07-04
2010-10-2917.26×2010-07-04
2010-11-3021.42×2010-10-03
2010-12-3123.01×2010-10-03
2011-01-3123.94×2010-10-03
2011-02-2825.28×2010-10-03
2011-03-3119.83×2010-12-31
2011-04-2920.47×2010-12-31
2011-05-3120.39×2011-04-03
2011-06-3019.59×2011-04-03
2011-07-2918.3×2011-04-03
2011-08-3117.54×2011-07-03
2011-09-3016.34×2011-07-03
2011-10-3117.8×2011-07-03
2011-11-3013.68×2011-10-02
2011-12-3014.75×2011-10-02
2012-01-3114.58×2011-10-02
2012-02-2916.26×2011-12-31
2012-03-3017.43×2011-12-31
2012-04-3017.63×2011-12-31
2012-05-3117.35×2012-04-01
2012-06-2918.24×2012-04-01
2012-07-3119.07×2012-04-01
2012-08-3117.59×2012-07-01
2012-09-2818.32×2012-07-01
2012-10-3118.34×2012-07-01
2012-11-3019.38×2012-09-30
2012-12-3119.43×2012-09-30
2013-01-3121.13×2012-09-30
2013-02-2821.2×2012-09-30
2013-03-2822.36×2012-09-30
2013-04-3022.52×2012-09-30
2013-05-3121.09×2012-09-30
2013-06-2821.7×2012-09-30
2013-07-3122.64×2012-09-30
2013-08-3021.85×2012-09-30
2013-09-3022.26×2012-09-30
2013-10-3123.77×2012-09-30
2013-11-2924.58×2012-09-30
2013-12-3123.73×2012-09-30
2014-01-3123.55×2012-09-30
2014-02-2824.87×2012-09-30
2014-03-3124.88×2012-09-30
2014-04-3024.23×2012-09-30
2014-05-3022.95×2012-09-30
2014-06-3022.99×2012-09-30
2014-07-3122.23×2012-09-30
2014-08-2922.77×2012-09-30
2014-09-3022.91×2012-09-30
2014-10-3123.2×2012-09-30
2014-11-2824.13×2012-09-30
2014-12-3124.13×2012-09-30
2015-01-3024.21×2012-09-30
2015-02-2726.59×2012-09-30
2015-03-318.99×2013-09-29
2015-04-308.77×2013-09-29
2015-05-298.98×2013-09-29
2015-06-308.67×2013-09-29
2015-07-319.32×2013-09-29
2015-08-318.33×2013-09-29
2015-09-308.12×2013-09-29
2015-10-308.74×2013-09-29
2015-11-308.47×2013-09-29
2015-12-318.34×2013-09-29
2016-01-297.88×2013-09-29
2016-02-297.67×2013-09-29
2016-03-3118.36×2014-06-29
2016-04-2920.27×2014-06-29
2016-05-3121.5×2014-06-29
2016-06-3021.81×2014-06-29
2016-07-2922.86×2014-06-29
2016-08-3121.56×2014-06-29
2016-09-3020.98×2014-06-29
2016-10-3119.65×2014-06-29
2016-11-3019.91×2014-06-29
2016-12-3020.12×2014-06-29
2017-01-3119.66×2014-06-29
2017-02-2821.14×2014-06-29
2017-03-3121.2×2014-06-29
2017-04-2821.02×2014-06-29
2017-05-3120.23×2014-06-29
2017-06-3020.81×2014-06-29
2017-07-3120.54×2014-06-29
2017-08-3121.02×2014-06-29
2017-09-2922.12×2014-06-29
2017-10-3121.72×2014-06-29
2017-11-3022.47×2014-06-29
2017-12-2922.44×2014-06-29
2018-01-3122.95×2014-06-29
2018-02-2822.5×2014-06-29
2018-03-2921.99×2014-06-29
2018-04-3022.68×2014-06-29
2018-05-3122.26×2014-06-29
2018-06-2922.48×2014-06-29
2018-07-3124.74×2014-06-29
2018-08-3125.72×2014-06-29
2018-09-2827.3×2014-06-29
2018-10-3126.68×2014-06-29
2018-11-3028.64×2014-06-29
2018-12-3127.04×2014-06-29
2019-01-3126.3×2014-06-29
2019-02-2826.86×2014-06-29
2019-03-2922.52×2018-12-31
2019-04-3021.54×2018-12-31
2019-05-3120.81×2019-03-31
2019-06-2821.71×2019-03-31
2019-07-3119.46×2019-03-31
2019-08-3015.94×2019-06-30
2019-09-3016.11×2019-06-30
2019-10-3117.21×2019-06-30
2019-11-2913.42×2019-09-29
2019-12-3113.65×2019-09-29
2020-01-3112.97×2019-09-29
2020-02-2811.64×2019-09-29
2020-03-3111.37×2019-09-29
2020-04-3013.36×2019-09-29
2020-05-2913.31×2019-09-29
2020-06-3011.39×2019-09-29
2020-07-3113.41×2019-09-29
2020-08-3113.17×2019-09-29
2020-09-3012.79×2019-09-29
2020-10-3012.36×2019-09-29
2020-11-3014.07×2019-09-29
2020-12-3113.52×2019-09-29
2021-01-2913.18×2019-09-29
2021-02-2612.3×2019-09-29
2021-03-3113.3×2019-09-29
2021-04-3014.19×2019-09-29
2021-05-2814.22×2019-09-29
2021-06-3014.38×2019-09-29
2021-07-3015.72×2019-09-29
2021-08-3116.92×2019-09-29
2021-09-3015.79×2019-09-29
2021-10-2916.06×2019-09-29
2021-11-3019.73×2019-09-29
2021-12-3121.68×2019-09-29
2022-01-3119.35×2019-09-29
2022-02-2812.32×2021-12-31
2022-03-3113.59×2021-12-31
2022-04-2912.88×2021-12-31
2022-05-3112.23×2022-04-03
2022-06-3012.09×2022-04-03
2022-07-2911.65×2022-04-03
2022-08-3110.43×2022-04-03
2022-09-3010.09×2022-04-03
2022-10-3110.74×2022-04-03
2022-11-3011.56×2022-04-03
2022-12-3011.82×2022-04-03
2023-01-3110.18×2022-04-03
2023-02-289.36×2022-04-03
2023-03-319.41×2022-04-03
2023-04-288.97×2022-04-03
2023-05-318.77×2022-04-03
2023-06-308.46×2022-04-03
2023-07-318.32×2022-04-03
2023-08-316.9×2022-07-03
2023-09-296.46×2022-07-03
2023-10-315.96×2022-07-03
2023-11-305.85×2022-10-02
2023-12-295.53×2022-10-02
2024-01-315.2×2022-10-02
2024-02-2971.37×2023-12-31
2024-03-2874.57×2023-12-31
2024-04-3068.84×2023-12-31
2024-05-31—2024-03-31
2024-06-28—2024-03-31
2024-07-31—2024-03-31
2024-08-30—2024-03-31
2024-09-30—2024-03-31
2024-10-31—2024-03-31
2024-11-29—2024-03-31
2024-12-31—2024-03-31
2025-01-31—2024-03-31
2025-02-2818.77×2024-12-31
2025-03-3117.99×2024-12-31
2025-04-3017.33×2024-12-31
2025-05-3016.68×2024-12-31
2025-06-3017.21×2024-12-31
2025-07-3116.54×2024-12-31
2025-08-2917.58×2024-12-31
2025-09-3018.09×2024-12-31
2025-10-3117.5×2024-12-31
2025-11-2814.97×2025-09-28
2025-12-3114.48×2025-09-28
2026-01-3015.37×2025-09-28
2026-02-2720.36×2025-12-31
2026-03-3120.67×2025-12-31
2026-04-3019.66×2025-12-31
2026-05-2920.03×2026-03-29
2026-06-3018.42×2026-03-29
2026-07-3119.14×2026-03-29
2026-08-3137.44×2026-06-28
2026-09-2537.72×2026-06-28
Mean 18.22×Median 18.03×109% above median

ROIC

% · Annual / TTM

—
NOPAT is undefined under this method: pretax profit must be positive and the effective tax rate must be between 0 and 100%.
Pfizer ROIC. Reported fiscal history.
Fiscal period% · Annual / TTM
FY 2009 Q2—
FY 2009 Q3—
FY 2009 Q4—
FY 2010 Q1—
FY 2010 Q2—
FY 2010 Q3—
FY 2010 Q4—
FY 2011 Q1—
FY 2011 Q2—
FY 2011 Q3—
FY 2011 Q4—
FY 2012 Q1—
FY 2012 Q2—
FY 2012 Q3—
FY 2012 Q4—
FY 2013 Q1—
FY 2013 Q2—
FY 2013 Q3—
FY 2013 Q4—
FY 2014 Q1—
FY 2014 Q2—
FY 2018 Q2—
FY 2018 Q3—
FY 2018 Q4—
FY 2019 Q1—
FY 2019 Q2—
FY 2019 Q3—
FY 2019 Q4—
FY 2020 Q1—
FY 2020 Q2—
FY 2020 Q3—
FY 2020 Q4—
FY 2021 Q1—
FY 2021 Q2—
FY 2021 Q3—
FY 2021 Q4—
FY 2022 Q1—
FY 2022 Q2—
FY 2022 Q3—
FY 2022 Q4—
FY 2023 Q1—
FY 2023 Q2—
FY 2023 Q3—
FY 2023 Q4—
FY 2024 Q1—
FY 2024 Q2—
FY 2024 Q3—
FY 2024 Q4—
FY 2025 Q1—
FY 2025 Q2—
FY 2025 Q3—
FY 2025 Q4—
FY 2026 Q1—
FY 2026 Q2—

Capital allocation

% of tracked cash uses

$533M
Pfizer capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2009 Q230.78% · $269MUnavailableUnavailableUnavailable69.22% · $605M100% · $874M
FY 2009 Q399.24% · $261M0% · $0M0% · $0MUnavailable0.76% · $2M100% · $263M
FY 2009 Q40.97% · $422M98.9% · $43,123M0% · $0MUnavailable0.13% · $57M100% · $43,602M
FY 2010 Q197.13% · $305MUnavailableUnavailableUnavailable2.87% · $9M100% · $314M
FY 2010 Q2100% · $373MUnavailableUnavailableUnavailableUnavailable100% · $373M
FY 2010 Q336.46% · $288MUnavailable63.29% · $500MUnavailable0.25% · $2M100% · $790M
FY 2010 Q499.64% · $547MUnavailable0% · $0MUnavailable0.36% · $2M100% · $549M
FY 2011 Q12.86% · $250M36.31% · $3,169M16.39% · $1,430MUnavailable44.44% · $3,878M100% · $8,727M
FY 2011 Q213.73% · $358M0% · $0M86.27% · $2,249MUnavailableUnavailable100% · $2,607M
FY 2011 Q317.54% · $454M0.73% · $19M81.53% · $2,110MUnavailable0.19% · $5M100% · $2,588M
FY 2011 Q48.08% · $598M1.27% · $94M43.37% · $3,211MUnavailable47.28% · $3,500M100% · $7,403M
FY 2012 Q19.41% · $254M28.98% · $782M61.49% · $1,659MUnavailable0.11% · $3M100% · $2,698M
FY 2012 Q217.95% · $294M0% · $0M81.81% · $1,340MUnavailable0.24% · $4M100% · $1,638M
FY 2012 Q313.4% · $285M0% · $0M86.27% · $1,835MUnavailable0.33% · $7M100% · $2,127M
FY 2012 Q48.74% · $494M4.74% · $268M60.02% · $3,394MUnavailable26.51% · $1,499M100% · $5,655M
FY 2013 Q14.18% · $202M0% · $0M95.78% · $4,626MUnavailable0.04% · $2M100% · $4,830M
FY 2013 Q25.17% · $309M0.25% · $15M54.57% · $3,263MUnavailable40.01% · $2,392M100% · $5,979M
FY 2013 Q36.89% · $278M0% · $0M93.06% · $3,754MUnavailable0.05% · $2M100% · $4,034M
FY 2013 Q46.12% · $417M0% · $0M68.2% · $4,647MUnavailable25.68% · $1,750M100% · $6,814M
FY 2014 Q113.03% · $292M0% · $0M53.41% · $1,197MUnavailable33.56% · $752M100% · $2,241M
FY 2014 Q217.36% · $278M0% · $0M82.64% · $1,323MUnavailable0% · $0M100% · $1,601M
FY 2018 Q213.36% · $424M0% · $0M0% · $0MUnavailable86.64% · $2,749M100% · $3,173M
FY 2018 Q333.11% · $547M0% · $0M66.89% · $1,105MUnavailable0% · $0M100% · $1,652M
FY 2018 Q411.09% · $685M0% · $0M81.43% · $5,030MUnavailable7.48% · $462M100% · $6,177M
FY 2019 Q13.73% · $460MUnavailable71.9% · $8,865MUnavailable24.37% · $3,004M100% · $12,329M
FY 2019 Q216.93% · $479MUnavailable0% · $0MUnavailable83.07% · $2,351M100% · $2,830M
FY 2019 Q355.61% · $565MUnavailable0% · $0MUnavailable44.39% · $451M100% · $1,016M
FY 2019 Q440.19% · $672M0% · $0M0% · $0MUnavailable59.81% · $1,000M100% · $1,672M
FY 2020 Q117.51% · $463MUnavailable0% · $0MUnavailable82.49% · $2,181M100% · $2,644M
FY 2020 Q2100% · $479MUnavailable0% · $0MUnavailable0% · $0M100% · $479M
FY 2020 Q361.4% · $525MUnavailable0% · $0MUnavailable38.6% · $330M100% · $855M
FY 2020 Q434.48% · $785M0% · $0M0% · $0MUnavailable65.52% · $1,492M100% · $2,277M
FY 2021 Q1100% · $554M0% · $0M0% · $0MUnavailable0% · $0M100% · $554M
FY 2021 Q2100% · $540M0% · $0M0% · $0MUnavailable0% · $0M100% · $540M
FY 2021 Q338.4% · $624M0% · $0M0% · $0MUnavailable61.6% · $1,001M100% · $1,625M
FY 2021 Q449.75% · $993M0% · $0M0% · $0MUnavailable50.25% · $1,003M100% · $1,996M
FY 2022 Q16.14% · $643M59.42% · $6,225M19.09% · $2,000MUnavailable15.36% · $1,609M100% · $10,477M
FY 2022 Q2100% · $751M0% · $0M0% · $0MUnavailable0% · $0M100% · $751M
FY 2022 Q3100% · $841M0% · $0M0% · $0MUnavailable0% · $0M100% · $841M
FY 2022 Q45.14% · $1,001M86.18% · $16,772M0% · $0MUnavailable8.68% · $1,689M100% · $19,462M
FY 2023 Q180.89% · $1,139M0% · $0M0% · $0MUnavailable19.11% · $269M100% · $1,408M
FY 2023 Q247.14% · $914M1.29% · $25M0% · $0MUnavailable51.57% · $1,000M100% · $1,939M
FY 2023 Q338.39% · $810M0% · $0M0% · $0MUnavailable61.61% · $1,300M100% · $2,110M
FY 2023 Q42.35% · $1,044M97.65% · $43,405M0% · $0MUnavailable0% · $0M100% · $44,449M
FY 2024 Q136.03% · $704MUnavailableUnavailableUnavailable63.97% · $1,250M100% · $1,954M
FY 2024 Q238.91% · $637MUnavailableUnavailableUnavailable61.09% · $1,000M100% · $1,637M
FY 2024 Q3100% · $651M0% · $0MUnavailableUnavailable0% · $0M100% · $651M
FY 2024 Q4100% · $917M0% · $0MUnavailableUnavailable0% · $0M100% · $917M
FY 2025 Q1100% · $564MUnavailableUnavailableUnavailable0% · $0M100% · $564M
FY 2025 Q214.15% · $618MUnavailableUnavailableUnavailable85.85% · $3,750M100% · $4,368M
FY 2025 Q3100% · $602MUnavailableUnavailableUnavailable0% · $0M100% · $602M
FY 2025 Q421.94% · $845MUnavailableUnavailableUnavailable78.06% · $3,007M100% · $3,852M
FY 2026 Q1100% · $436MUnavailableUnavailableUnavailableUnavailable100% · $436M
FY 2026 Q2100% · $533MUnavailableUnavailableUnavailableUnavailable100% · $533M

Tracked cash uses · SBC excluded

Sources and calculations

Company filings · USD · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for Pfizer.

All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.

SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.

Revenue
Reported revenue from company filings.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Net margin
Reported net income / revenue × 100.
P/E
Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
ROIC
NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
Capital allocation
Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.
Reported revenue and sources